Mission Pharmacal Launches Citracal(R) Prenatal 90 + DHA With life'sDHA(TM)

COLUMBIA, Md., - DHA omega-3 innovator Martek Biosciences Corporation (NASDAQ: MATK) announced today that Mission Pharmacal, maker of the Citracal® brand of calcium citrate supplements and prenatal vitamins, has launched a new prescription product, Citracal® Prenatal 90 + DHA. As the latest addition to the company's prenatal vitamin family, Citracal® 90 + DHA is the second prenatal vitamin containing life'sDHA™ in the Citracal family of products. Citracal® Prenatal 90 + DHA with life'sDHA™ is designed to meet the nutritional needs of women before, during and after pregnancy.

"Martek is pleased to be working with Mission on their second product containing life'sDHA™," said Steve Dubin, CEO of Martek Biosciences. "The success of Mission's first product, coupled with the launch of Citracal® 90 + DHA, illustrates how both expectant mothers and the healthcare industry are recognizing the important health benefits of DHA."

The Citracal® prenatal pack includes a balanced dose of prescription- strength vitamins and minerals including 90 mg of carbonyl iron, a higher dose than many prenatal vitamins on the market today, plus 250 mg capsules of Martek's life'sDHA™. Martek's life'sDHA™ is a vegetarian form of DHA omega-3, a long-chain polyunsaturated fatty acid that serves as a primary building block for the brain and eyes and supports brain, eye and cardiovascular health throughout life. Studies have shown that increased availability of DHA omega-3 during pregnancy and lactation nourishes the neurological, visual and nervous system development of babies and may play an important role in long-term infant heart health and maternal well-being. Yet despite its importance, Americans have among the lowest dietary intakes of DHA omega-3 in the world. Additionally, expert bodies such as the FDA have advised pregnant and nursing women to limit their fish consumption (the main dietary source of DHA omega-3) due to the potentially high levels of contaminants such as mercury found in certain fish.

Martek's life'sDHA™ is unique in the market because it is derived from a sustainable and vegetarian source. Made from microalgae under tightly controlled manufacturing conditions, life'sDHA™ is free of oceanic contaminants that may be present in certain fish or fish oils. Microalgae are the only vegetarian source of DHA omega-3, the key omega-3 for brain development and function.

Citracal® Prenatal 90 + DHA is marketed by Mission Pharmacal, a privately held pharmaceutical company based in San Antonio, Texas. For more than 60 years, the company has been dedicated to identifying unmet health needs in the marketplace and developing innovative prescription and over-the- counter products to meet them. Currently, Mission Pharmacal provides physicians and consumers with pharmaceutical, nutritional and diagnostic products. For more information, visit http://www.missionpharmacal.com/ or http://www.citracalprenatal.com/ .

Martek Biosciences Corporation (NASDAQ: MATK) is a leader in the innovation and development of DHA omega-3 products that promote health and wellness through every stage of life. The Company produces life'sDHA™, a sustainable and vegetarian source of DHA omega-3, for use in foods, beverages, infant formula, and supplements, and ARA (arachidonic acid), an omega-6 fatty acid, for use in infant formula. For more information on Martek Biosciences, visit http://www.martek.com/.

Sections of this release contain forward-looking statements concerning, among other things, expectations regarding Mission Pharmacal's new Citracal® Prenatal 90 + DHA, customer acceptance of Citracal® Prenatal 90 + DHA with life'sDHA™ and widespread use of life'sDHA™. These statements are based upon numerous assumptions which Martek cannot control and involve risks and uncertainties that could cause actual results to differ. These statements should be understood in light of the risk factors set forth in the Company's filings with the Securities and Exchange Commission, including, but not limited to, the Company's Form 10-K for the fiscal year ended October 31, 2006 and other filed reports on Form 10-K, Form 10-K/A, Form 10-Q and Form 8-K.

  Cassie France-Kelly
  Public Relations, Martek
  (443) 542-2116
  [email protected]

  Kyle Stults
  Investor Relations, Martek
  (410) 740-0081
  [email protected]
Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.